Published TCIMAIL newest issue No.200 | Product Document Searching Made Easy by 2D Code! | TCI Life Science News December 2025 | [TCIPracticalExample] Suzuki-Miyaura Coupling Using Encapsulated... | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
请选择数量
CAS RN: 755037-03-7 | 產品號碼: R0142
產品規格
| Appearance | White to Light yellow to Light orange powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Elemental analysis(Nitrogen) | 11.00 to 12.20 % |
性質
| 熔點 | 208 °C |
GHS
| 圖形表示 |
|
| 信號詞 | Warning |
| 危險性說明 | H302 : Harmful if swallowed. H361 : Suspected of damaging fertility or the unborn child. H373 : May cause damage to organs through prolonged or repeated exposure. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. P405 : Store locked up. |
相關法規
運輸資料
| HS編碼* | 2933.39-000 |
Application
Regorafenib: A Multikinase Inhibitor of Tumour Angiogenesis, Oncogenesis and the Tumour Microenvironment
Regorafenib (BAY 73-4506) is a potent diphenylurea multikinase inhibitor of tumour angiogenesis (VEGFR1，VEGFR2，VEGFR3，TIE2), oncogenesis (KIT, RET, RAF-1, BRAF, BRAFV600E), and the tumour microenvironment (PDGFR-β, FGFR). Regorafenib has promising antineoplastic activity in various tumor types. Regorafenib is mainly metabolized by CYP3A4, and the major human metabolites M-2 (N-oxide) and M-5 (N-oxide and N-desmethyl) are reported to exhibited similar efficacies compared to regorafenib in in vitro and in vivo models. For your reference, [A2979] is a key synthetic intermediate of regorafenib. (The product is for research purpose only.)
References
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- Regorafenib for cancer (a review)
- Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
- A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry
- Determination of regorafenib (BAY 73-4506) and its major human metabolites BAY 75-7495 (M-2) and BAY 81-8752 (M-5) in human plasma by stable-isotope dilution liquid chromatography-tandem mass spectrometry
PubMed Literature
文檔
產品介紹報導
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。